A PHASE I–II STUDY OF LIVE ATTENUATED VARICELLA-ZOSTER VIRUS VACCINE TO BOOST IMMUNITY IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN WITH PREVIOUS VARICELLA

A PHASE I–II STUDY OF LIVE ATTENUATED VARICELLA-ZOSTER VIRUS VACCINE TO BOOST IMMUNITY IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN WITH PREVIOUS VARICELLA

Herpes zoster, may be severe and recurrent in HIV-infected children. We determined the safety and immunogenicity of live attenuated varicella-zoster virus (VZV) vaccine in 46 HIV-infected children who had experienced varicella. There were no serious adverse events. Two years after vaccination 82% of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Pediatric infectious disease journal 2009-07, Vol.28 (7), p.653-655
Hauptverfasser: Gershon, Anne A, Levin, Myron J, Weinberg, Adriana, Song, Lin-Yee, LaRussa, Philip S, Steinberg, Sharon P, Bartlett, Patterson
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies, Viral - blood
Biological and medical sciences
Chickenpox Vaccine - adverse effects
Chickenpox Vaccine - immunology
Child
Herpes Zoster - prevention & control
Herpesvirus 3, Human - immunology
HIV Infections - immunology
Human viral diseases
Humans
Immunization, Secondary - methods
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious diseases
Longitudinal Studies
Male
Medical sciences
T-Lymphocytes - immunology
Vaccines, Attenuated - adverse effects
Vaccines, Attenuated - immunology
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Herpes zoster, may be severe and recurrent in HIV-infected children. We determined the safety and immunogenicity of live attenuated varicella-zoster virus (VZV) vaccine in 46 HIV-infected children who had experienced varicella. There were no serious adverse events. Two years after vaccination 82% of subjects remained VZV-antibody positive and 60% had VZV-specific cell-mediated immunity. No child developed herpes zoster.
ISSN:0891-3668
1532-0987
DOI:10.1097/INF.0b013e3181998f06